These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34620695)

  • 1. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the
    Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A
    Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
    Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
    Markati T; Fisher G; Ramdas S; Servais L
    Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risdiplam in Type 1 Spinal Muscular Atrophy.
    Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
    N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
    Cleary Y; Gertz M; Grimsey P; Günther A; Heinig K; Ogungbenro K; Aarons L; Galetin A; Kletzl H
    Clin Pharmacol Ther; 2021 Dec; 110(6):1547-1557. PubMed ID: 34347881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
    Ratni H; Ebeling M; Baird J; Bendels S; Bylund J; Chen KS; Denk N; Feng Z; Green L; Guerard M; Jablonski P; Jacobsen B; Khwaja O; Kletzl H; Ko CP; Kustermann S; Marquet A; Metzger F; Mueller B; Naryshkin NA; Paushkin SV; Pinard E; Poirier A; Reutlinger M; Weetall M; Zeller A; Zhao X; Mueller L
    J Med Chem; 2018 Aug; 61(15):6501-6517. PubMed ID: 30044619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
    Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
    J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of single-stranded nucleic acids by small-molecule splicing modulators.
    Tang Z; Akhter S; Ramprasad A; Wang X; Reibarkh M; Wang J; Aryal S; Thota SS; Zhao J; Douglas JT; Gao P; Holmstrom ED; Miao Y; Wang J
    Nucleic Acids Res; 2021 Aug; 49(14):7870-7883. PubMed ID: 34283224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risdiplam: First Approval.
    Dhillon S
    Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents.
    Mueller L; Barrow P; Jacobsen B; Ebeling M; Weinbauer G
    Reprod Toxicol; 2023 Jun; 118():108360. PubMed ID: 36894038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
    Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
    Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
    Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F;
    J Neurol; 2024 Aug; 271(8):4871-4884. PubMed ID: 38733387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
    Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
    Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
    Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
    J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
    Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.